Wave Life Sciences Ltd.
NASDAQ:WVE · NASDAQ Global Market
+$0.10 today
Vol 5.07M · Avg 4.86M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$204.4M -110.7% | -$97.0M -68.7% | -$57.5M +64.5% | -$161.8M -32.4% | -$122.2M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $8.9M +2.2% | $8.7M -5.9% | $9.2M -9.0% | $10.1M +2.8% | $9.8M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 +100.0% | -$12.6M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $13.1M +34.2% | $9.8M -43.0% | $17.2M +4.8% | $16.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$16.9M +77.7% | -$75.8M -497.4% | $19.1M +183.9% | $6.7M -4.1% | $7.0M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $146.0K -99.3% | $19.7M +193.3% | -$21.1M | $0 -100.0% | $30.0M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 -100.0% | $2.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$561.0K -116.4% | $3.4M +191.0% | -$3.8M -140.2% | $9.3M +242.3% | -$6.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$16.5M +83.3% | -$98.9M -325.2% | $43.9M +1772.8% | -$2.6M +85.8% | -$18.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $25.0M | $0 | $0 -100.0% | $12.0K -99.9% | $12.6M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$187.5M -24.1% | -$151.0M -677.2% | -$19.4M +84.8% | -$127.8M -43.6% | -$89.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$718.0K +23.5% | -$938.0K +15.9% | -$1.1M +18.1% | -$1.4M -143.0% | -$560.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 +100.0% | -$75.0M | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 -100.0% | $75.0M | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 -100.0% | $106.0K | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$718.0K +23.5% | -$938.0K +15.9% | -$1.1M +11.2% | -$1.3M -124.1% | -$560.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $488.2M +106.7% | $236.2M +79.9% | $131.3M +150.9% | $52.3M -4.8% | $55.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $17.7M +1309.2% | $1.3M -91.5% | $14.9M +1632.3% | $858.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $488.2M +92.3% | $253.9M +91.6% | $132.5M +97.3% | $67.2M +20.3% | $55.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $12.0K +108.7% | -$138.0K -45.3% | -$95.0K +54.8% | -$210.0K -1.0% | -$208.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $300.0M +194.8% | $101.8M -9.0% | $111.9M +280.3% | -$62.1M -82.9% | -$33.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$187.5M -23.4% | -$152.0M -639.6% | -$20.5M +84.1% | -$129.1M -44.2% | -$89.6M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.27B
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.73B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.70B
Precigen, Inc.
NASDAQ:PGEN
$1.39B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.28B
Tourmaline Bio, Inc.
TRML
$1.23B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$880.93M
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$855.13M
Upstream Bio, Inc.
NASDAQ:UPB
$340.67M
SEC Filings
Recent regulatory filings
No filings found.
Does WVE generate free cash flow?
Wave Life Sciences Ltd. (WVE) generated -$187,493,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does WVE produce?
Operating cash flow was -$187,493,000.00, before capital expenditures of $718,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.